Cost-Effectiveness of Improvements in Diagnosis and Treatment Accessibility for Tuberculosis Control in India

摘要

SettingInaccurate diagnosis and care inaccessibility undercut the effectiveness of high-quality tuberculosis (TB) treatment and select for resistance. Rapid diagnosis systems (e.g., GeneXpert) for TB diagnosis and drug-susceptibility testing (DST), and programs that provide high-quality DOTS TB treatment to patients in the unregulated private sector (pubic private mix, or PPM), may help address these challenges, albeit at increased cost.